Article Contents ::
- 1 The Brand Name PACIMID (VI) Has Generic Salt :: Midazolam
- 2 PACIMID (VI) Is From Company ZENOTECH LAB. Priced :: Rs. 58
- 3 PACIMID (VI) have Midazolam is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PACIMID (VI) Has Generic Salt :: Midazolam
PACIMID (VI) Is From Company ZENOTECH LAB. Priced :: Rs. 58
PACIMID (VI) have Midazolam is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Midazolam | INJ | Rs. 58 | 10MG/10ML |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10MG/10ML |
PACIMID (VI) | ZENOTECH LAB. | 10MG/10ML | 10MG/10ML | Rs. 58 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From ZENOTECH LAB. :: PACIMID (VI) | Midazolam | Anti Infectives | Miscellaneous |
Indications for Drugs ::
Insomnia, Sedation, Induction of anesthesia
Drug Dose ::
Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure. Intravenous administration: Endoscopic or Cardiovascular Procedures In healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg. Induction of Anesthesia The dose is 10-15 mg I. V. Intramuscular administration: Adult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg. Children: 0.15-0.20 mg/kg. Elderly and debilitated patients: 0.025-0.05 mg/kg Rectal administration in children: For preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia.
Contraindication ::
Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.
Drug Precautions ::
Midazolam IV should be administered very slowly.
Drug Side Effects ::
At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.
Pregnancy category ::
4
Drug Mode of Action ::
Midazolam is a short-acting benzodiazepine. It exerts sedative and hypnotic, muscle relaxant, anxiolytic and anticonvulsant actions. While the probable anxiolytic action might be as a result of the drug’s ability to increase glycine inhibitory neurotransmitter level, the hypnotic/anaesthetic action may be due to the occupation of the benzodiazepine and GABA receptors leading to membrane hyperpolarisation and neuronal inhibition, and further interfering with the re-uptake of GABA at the synapses.
Drug Interactions ::
Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.